Skip to main content

Advertisement

SpringerLink
Log in

Predictive factors for overall and progression-free survival, and dissemination in oligodendroglial tumors

  • Clinical study - Patient study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

The pattern of recurrence and predictive factors for tumor progression, dissemination and survival in oligodendroglial tumors were investigated. 56 consecutive patients with oligodendroglial tumors were retrospectively analyzed to determine the predictive significance of various factors, including World Health Organization grade, loss of chromosomes 1p and 19q, and immunohistochemical features of TP53, O6-methylguanine-deoxyribonucleic-acid-methyltransferase, CD44H, nestin, and Ki-67. Eleven patients developed dissemination, and had significantly shorter post-progression survival compared to ten patients with local recurrence. Univariate analysis showed that retention of chromosome 1p or 19q, Ki-67 labeling index ≥ 25%, diffuse expression of nestin, and p53 labeling index ≥ 10% were unfavorable factors for overall, progression-free, and dissemination-free survival. Multivariate analysis showed that Ki-67 labeling index ≥ 25% and diffuse expression of nestin were significant for dissemination-free survival. In conclusion, post-progression survival shows significant differences between patients with local and disseminated recurrence. Ki-67 labeling index and nestin expression pattern are useful markers to predict dissemination.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. The Committee of Brain Tumor Registry of Japan (2003) Report of brain tumor registry of Japan (1969–1996). Neurol Med Chir Tokyo 43(Suppl):1–111. doi:10.2176/nmc.43.1

    Article  Google Scholar 

  2. Coons SW, Johnson PC, Scheithauer BW et al (1997) Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79:1381–1393. doi:10.1002/(SICI)1097-0142(19970401)79:7<1381::AID-CNCR16>3.0.CO;2-W

    Article  PubMed  CAS  Google Scholar 

  3. Fortin D, Cairncross GJ, Hammond RR (1999) Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery 45:1279–1291. doi:10.1097/00006123-199912000-00001

    Article  PubMed  CAS  Google Scholar 

  4. Cairncross G, Berkey B, Shaw E et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714. doi:10.1200/JCO.2005.04.3414

    Article  PubMed  CAS  Google Scholar 

  5. van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organization for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715–2722. doi:10.1200/JCO.2005.04.6078

    Article  PubMed  CAS  Google Scholar 

  6. McLendon RE, Herndon JEII, West B et al (2005) Survival analysis of presumptive prognostic markers among oligodendrogliomas. Cancer 104:1693–1699. doi:10.1002/cncr.21362

    Article  PubMed  CAS  Google Scholar 

  7. Levin N, Lavon I, Zelikovitsh B et al (2006) Progressive low-grade oligodendrogliomas Response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 106:1759–1765. doi:10.1002/cncr.21809

    Article  PubMed  CAS  Google Scholar 

  8. Hagel C, Stavrou DK (1999) CD44 expression in primary and recurrent oligodendrogliomas and in adjacent gliotic brain tissue. Neuropathol Appl Neurobiol 25:313–318. doi:10.1046/j.1365-2990.1999.00181.x

    Article  PubMed  CAS  Google Scholar 

  9. Coons SW, Johnson PC, Perl DK (1997) The prognostic significance of Ki-67 labeling indices for oligodendroglioma. Neurosurgery 41:878–885. doi:10.1097/00006123-199710000-00021

    Article  PubMed  CAS  Google Scholar 

  10. Dehghani F, Schachenmayr W, Laun A et al (1998) Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases. Acta Neuropathol 95:493–504. doi:10.1007/s004010050830

    Article  PubMed  CAS  Google Scholar 

  11. Strojnik T, Røsland GV, Sakariassen PO et al (2007) Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival. Surg Neurol 68:133–143. doi:10.1016/j.surneu.2006.10.050

    Article  PubMed  Google Scholar 

  12. Zulewski H, Abraham EJ, Gerlach MJ et al (2001) Multipotential nestin-positive stem cells isolated from adult pancreatic islets differentiate ex vivo into pancreatic endocrine, exocrine, and hepatic phenotypes. Diabetes 50:521–533. doi:10.2337/diabetes.50.3.521

    Article  PubMed  CAS  Google Scholar 

  13. Lebrun C, Fontaine D, Bourg V et al (2007) Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur J Neurol 14:391–398. doi:10.1111/j.1468-1331.2007.01675.x

    Article  PubMed  CAS  Google Scholar 

  14. Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64:479–489

    PubMed  CAS  Google Scholar 

  15. Parsa AT, Wachhorst S, Lamborn KR et al (2005) Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults. J Neurosurg 102:622–628

    Article  PubMed  Google Scholar 

  16. Grabb PA, Albright AL, Pang D (1992) Dissemination of supratentorial malignant gliomas via cerebrospinal fluid in children. Neurosurgery 30:64–71

    Article  PubMed  CAS  Google Scholar 

  17. Kato H, Fujimura M, Kumabe T et al (2004) PTEN gene mutation and high MIB-1 labeling index may contribute to dissemination in patients with glioblastoma. J Clin Neurosci 11:37–41

    Article  PubMed  CAS  Google Scholar 

  18. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO classification of tumours of the central nervous system, 4th edn. International Agency for Research on Cancer Press, Lyon, pp 54–67

    Google Scholar 

  19. Ogawa K, Yoshii Y, Toita T et al (2006) Hyperfractionated radiotherapy and multi-agent chemotherapy (procarbazine, ACNU and vincristine) for high-grade gliomas: a prospective study. Anticancer Res 26:2457–2462

    PubMed  CAS  Google Scholar 

  20. Cunningham JM, Kimmel DW, Scheithauer BW et al (1997) Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value. J Neurosurg 86:121–130

    PubMed  CAS  Google Scholar 

  21. Friedman HS, McLendon RE, Kerby T et al (1998) DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16:3851–3857

    PubMed  CAS  Google Scholar 

  22. Saito R, Kumabe T, Jokura H et al (2003) Symptomatic spinal dissemination of malignant astrocytoma. J Neurooncol 61:227–235

    Article  PubMed  Google Scholar 

  23. Smith JS, Parney IF, Lamborn KR et al (2007) Treatment for posterior fossa dissemination of primary supratentorial glioma. J Neurosurg 106:567–574

    Article  PubMed  Google Scholar 

  24. Khoshyomn S, Lew S, DeMattia J et al (1999) Brain tumor invasion rate measured in vitro does not correlate with Ki-67 expression. J Neurooncol 45:111–116

    Article  PubMed  CAS  Google Scholar 

  25. Wei LC, Shi M, Cao R, Chen LW et al (2007) Nestin small interfering RNA (siRNA) reduces cell growth in cultured astrocytoma cells. Brain Res 27(1196):103–112

    Google Scholar 

  26. Mangiola A, Lama G, Giannitelli C et al (2007) Stem cell marker nestin and c-Jun NH2-terminal kinases in tumor and peritumor areas of glioblastoma multiforme: possible prognostic implications. Clin Cancer Res 13:6970–6977

    Article  PubMed  CAS  Google Scholar 

  27. Günther HS, Schmidt NO, Phillips HS et al. (2008) Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 27:2897–2909

    Article  PubMed  CAS  Google Scholar 

  28. Pilkington GJ (1994) Tumor cell migration in the central nervous system. Brain Pathol 4:157–166

    Article  PubMed  CAS  Google Scholar 

  29. Weller M, Berger H, Hartmann C et al (2007) Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin Cancer Res 13:6933–6937

    Article  PubMed  CAS  Google Scholar 

  30. Stander M, Peraud A, Leroch B et al (2004) Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma. Cancer 101:1028–1035

    Article  PubMed  CAS  Google Scholar 

  31. Aghi M, Gaviani P, Henson JW et al (2005) Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin Cancer Res 11:8600–8605

    Article  PubMed  CAS  Google Scholar 

  32. Giese A (2003) Glioma invasion—pattern of dissemination by mechanisms of invasion and surgical intervention, pattern of gene expression and its regulatory control by tumorsuppressor p53 and proto-oncogene ETS-1. Acta Neurochir Suppl 88:153–162

    PubMed  CAS  Google Scholar 

  33. Brandes AA, Tosoni A, Cavallo G et al (2006) Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GINCO study. J Clin Oncol 24:4746–4753

    Article  PubMed  CAS  Google Scholar 

  34. Kamiryo T, Tada K, Shiraishi S et al (2004) Correlation between promoter hypermethylation of the O6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy. Neurosurgery 54:349–357

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work supported in part by Grants-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (No. 18791005). The authors do not report any conflict of interest concerning the materials or methods used in this study or findings specified in this paper.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Miyagi, Japan

    Masayuki Kanamori, Toshihiro Kumabe, Yukihiko Sonoda & Teiji Tominaga

  2. Division of Epidemiology, Miyagi Cancer Center Research Institute, Natori, Miyagi, Japan

    Yoshikazu Nishino

  3. Department of Pathology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan

    Mika Watanabe

Authors
  1. Masayuki Kanamori
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toshihiro Kumabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yukihiko Sonoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshikazu Nishino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mika Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Teiji Tominaga
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toshihiro Kumabe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kanamori, M., Kumabe, T., Sonoda, Y. et al. Predictive factors for overall and progression-free survival, and dissemination in oligodendroglial tumors. J Neurooncol 93, 219–228 (2009). https://doi.org/10.1007/s11060-008-9762-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-008-9762-7

Keywords

Search

Navigation